Patents by Inventor Mark Alfonso
Mark Alfonso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240069907Abstract: Historic context data is automatically associated with particular pieces of source code by retrieval data structures. Ephemeral information is preserved, such as how a piece of code originated operationally and was changed over time, which research sources informed the code's origination and changes, and why particular changes in the code were made. Code may be rolled back to an earlier version based on parameters such as whether code had been refactored, or results of testing or static analysis. Rollback goes beyond editor undo actions, and a developer need not specify a timestamp or a version number. Developer documentation burdens are reduced, developer understanding is increased, and code quality is enhanced, by providing ready access to the code's software development context history data. Some actions made possible include highlighting code that was generated automatically by autocompletion or otherwise, highlighting refactored code, and highlighting pasted code, among other actions.Type: ApplicationFiled: August 24, 2022Publication date: February 29, 2024Inventors: Peter GROENEWEGEN, Mark Alistair WILSON-THOMAS, German David OBANDO CHACON, David Ellis PUGH, Mikhail BRESLAV, Oscar Alfonso OBESO TREJO
-
Patent number: 9259397Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.Type: GrantFiled: October 23, 2001Date of Patent: February 16, 2016Assignee: Purdue Pharma L.P.Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
-
Publication number: 20150182474Abstract: The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. 1(a)). The article is comprised of an outer layer (1) having an inner layer-facing side and an opposite side; an inner layer (3) having an outer layer-facing side and an opposite side, the inner layer (3) joined to the outer layer (1) to form one or more closed material reservoir (2) between the outer layer-facing side of the inner layer (2) and the inner layer-facing side of the outer layer (1); and adhesive (4) covering a first portion of the opposite side of the inner layer (3), wherein the adhesive (4) is a heat activated adhesive that changes color and/or is activated when the article is subjected to elevated temperatures, thereby sealing the transdermal dosage form within the article.Type: ApplicationFiled: August 12, 2014Publication date: July 2, 2015Applicant: PURDUE PHARMA L.P.Inventors: Geraldine Marcenyac, Mark Alfonso, Lane Gehrlein, Stephen Howard, Lino Tavares, Ronald Greenbaum, Seth Levy, Benjamin Oshlack
-
Publication number: 20140199383Abstract: The present invention relates to transdermal dosage form (FIGS. 1-3) comprising at least one activating agent and at least one inactivating agent. The dosage form (FIGS. 1-3) releases the inactivating agent upon disruption of the dosage form (FIGS. 1-3) thereby preventing or hindering misuse of the active agent contained in the dosage form (FIGS. 1-3).Type: ApplicationFiled: January 21, 2014Publication date: July 17, 2014Applicant: PURDUE PHARMA L.P.Inventors: Lino Tavares, Bruce E. Reidenberg, Richard S. Sackler, Curtis Wright, Mark A. Alfonso, Benjamin Oshlack, James P. Cassidy, Anthony E. Carpanzano, Rampurna P. Gullapalli, Ihor Shevchuk
-
Patent number: 8496960Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.Type: GrantFiled: October 23, 2002Date of Patent: July 30, 2013Assignee: Purdue Pharma L.P.Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
-
Publication number: 20080262284Abstract: The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. 1(a)). The article is comprised of an outer layer (1) having an inner layer-facing side and an opposite side; an inner layer (3) having an outer layer-facing side and an opposite side, the inner layer (3) joined to the outer layer (1) to form one or more closed material reservoir (2) between the outer layer-facing side of the inner layer (2) and the inner layer-facing side of the outer layer (1); and adhesive (4) covering a first portion of the opposite side of the inner layer (3), wherein the adhesive (4) is a heat activated adhesive that changes color and/or is activated when the article is subjected to elevated temperatures, thereby sealing the transdermal dosage form within the article.Type: ApplicationFiled: June 27, 2008Publication date: October 23, 2008Applicant: PURDUE PHARMA L.P.Inventors: Geraldine Marcenyac, Mark Alfonso, Lane Gehrlein, Stephen Howard, Lino Tavares, Ronald Greenbaum, Seth Levy, Benjamin Oshlack
-
Patent number: 7018649Abstract: A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.Type: GrantFiled: October 23, 2001Date of Patent: March 28, 2006Assignee: Euro-Celtique, S.A.Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
-
Publication number: 20050064022Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.Type: ApplicationFiled: October 23, 2002Publication date: March 24, 2005Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
-
Publication number: 20050031678Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.Type: ApplicationFiled: September 20, 2004Publication date: February 10, 2005Applicant: Euro-Celtique S.AInventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
-
Publication number: 20040241218Abstract: The present invention relates to transdermal dosage form (FIG. 1-3) comprising at least one activating agent and at least one inactivating agent. The dosage form (FIG. 1-3) releases the inactivating agent upon disruption of the dosage form (FIG. 1-3) thereby preventing or hindering misuse of the active agent contained in the dosage form (FIG. 1-3).Type: ApplicationFiled: November 20, 2003Publication date: December 2, 2004Inventors: Lino Tavares, Bruce E Reidenberg, Richard S Sackler, Curtis Wright, Mark A Alfonso, Benjamin Oshlack, James P Cassidy, Anthony E Carpanzano, Rampurna P Gullapalli, Ihor Shevchuk
-
Publication number: 20040146547Abstract: The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. 1(a)). The article is comprised of an outer layer (1) having an inner layer-facing side and an opposite side; an inner layer (3) having an outer layer-facing side and an opposite side, the inner layer (3) joined to the outer layer (1) to form one or more closed material reservoir (2) between the outer layer-facing side of the inner layer (2) and the inner layer-facing side of the outer layer (1); and adhesive (4) covering a first portion of the opposite side of the inner layer (3), wherein the adhesive (4) is a heat activated adhesive that changes color and/or is activated when the article is subjected to elevated temperatures, thereby sealing the transdermal dosage form within the article.Type: ApplicationFiled: November 20, 2003Publication date: July 29, 2004Inventors: Geraldine Marcenyac, Mark Alfonso, Lane Gehrlein, Stephen Howard, Lino Tavares, Ronald Greenbaum, Seth Levy, Benjamin Oshlack
-
Patent number: 6642275Abstract: A dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.Type: GrantFiled: August 16, 2001Date of Patent: November 4, 2003Assignee: Euro- Celtique, S.A.Inventors: Mark Alfonso, Paul Goldenheim, Richard Sackler
-
Publication number: 20030072791Abstract: A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.Type: ApplicationFiled: October 23, 2001Publication date: April 17, 2003Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
-
Publication number: 20030035828Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.Type: ApplicationFiled: October 23, 2001Publication date: February 20, 2003Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
-
Publication number: 20020198215Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.Type: ApplicationFiled: October 23, 2001Publication date: December 26, 2002Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
-
Publication number: 20020022663Abstract: A dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.Type: ApplicationFiled: August 16, 2001Publication date: February 21, 2002Inventors: Mark Alfonso, Paul Goldenheim, Richard Sackler
-
Publication number: 20010049391Abstract: A dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.Type: ApplicationFiled: November 5, 1999Publication date: December 6, 2001Inventors: MARK ALFONSO, PAUL GOLDENHEIM, RICHARD SACKLER
-
Patent number: 6017963Abstract: A dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.Type: GrantFiled: November 14, 1995Date of Patent: January 25, 2000Assignee: Euro-Celtique, S.A.Inventors: Mark Alfonso, Paul Goldenheim, Richard Sackler